Form 4: GeneDx CFO Sells Shares for Tax Obligations

GeneDx Holdings Corp.'s CFO, Kevin Feeley, sold 388 shares of Class A Common Stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), reported transactions on October 29, 2025.
• Feeley acquired 753 shares of Class A Common Stock upon the settlement of restricted stock units (RSUs) for no consideration.
• Concurrently, Feeley disposed of 388 shares of Class A Common Stock at a price of $136.54 per share.
• The sale was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations related to the RSU vesting and was not a discretionary sale.
• Following these transactions, Feeley directly beneficially owns 3,757 shares of Class A Common Stock.
• Additionally, Feeley beneficially owns RSUs representing contingent rights to receive up to 123,880 shares of Class A Common Stock and options to purchase up to 25,906 shares of Class A Common Stock, which vest according to their respective terms.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While there's a share sale, it's non-discretionary for tax purposes, and the underlying RSU vesting indicates continued executive retention and alignment with company performance, which is a positive signal.

Positives

• The vesting of 753 restricted stock units indicates continued service and retention of a key executive, Kevin Feeley.
• The underlying RSU awards incentivize long-term performance and alignment with shareholder interests.

Negatives

• The sale of 388 shares, even for tax purposes, slightly reduces the direct beneficial ownership of Class A Common Stock by the Chief Financial Officer.

Future Outlook

The remaining restricted stock units and options held by the CFO are subject to future vesting schedules, with the last RSU tranche scheduled to vest on April 29, 2026, contingent on continued service.

Management Comments

• The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This transaction is a routine 'sell to cover' event, common in the biotechnology and healthcare sectors, where executives receive equity compensation in the form of restricted stock units or options. Such sales are standard practice for managing tax liabilities upon vesting.

Stakeholder Impact

• Shareholders: Minor, as the sale is non-discretionary and for tax purposes, not indicative of a change in management's outlook. The underlying RSU vesting is a positive for executive retention.
• Employees: No direct impact mentioned.

Next Steps

• Continued vesting of remaining RSUs and options held by Kevin Feeley according to their respective terms, with the final RSU tranche vesting on April 29, 2026.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell to cover' transaction by the CFO to satisfy tax obligations upon RSU vesting. It does not reflect a change in the company's fundamentals, strategic direction, or management's discretionary view on the stock's future performance. Therefore, it provides no new information that would warrant a change from a 'hold' position based solely on this filing.

Keywords

GeneDx Holdings Corp, WGS, Kevin Feeley, CFO, Insider Trading, Form 4, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, Executive Compensation